Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

Cancers

JustineD. Mintern¹  Christophe Macri¹  Ben Wylie²  Jason Waithman³ 

[1] Department of Biochemistry and Molecular Biology, The University of Melbourne, Bio21, Molecular Science and Biotechnology Institute, Parkville, VIC 3010, Australia;Phylogica, Harry Perkins Institute, QEII Medical Centre, Nedlands, WA 6009, Australia;Telethon Kids Institute, University of Western Australia, Northern Entrance, Perth Children’s Hospital, Nedlands, WA 6009, Australia;

关键词: tumor-associated dendritic cells;    DC-based therapy;    immunotherapy;    checkpoint blockade;    immunosuppression;    novel therapies;    cancer;   

DOI  :  10.3390/cancers11040521

来源: DOAJ

【 摘 要 】

Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy.

【 授权许可】

Unknown